[Comment] Sequential metastasis-directed therapy in renal-cell carcinoma: promising, but unproven without randomised evidence

Published in

The Lancet Oncology, The Lancet (Reed Elsevier)

Content

The advent of metastasis-directed therapy has reshaped treatment strategies across various solid tumours, including renal-cell carcinoma.1,2 Once deemed to be radioresistant, renal-cell carcinoma can now be effectively treated in select patients using stereotactic ablative radiotherapy.3,4 In this context, the phase 2 trial by Chad Tang and colleagues, published in The Lancet Oncology,5 adds to the growing evidence for sequential metastasis-directed therapy in patients with systemic therapy-naive oligometastatic clear-cell renal-cell carcinoma—a strategy first reported in 2019 and explored prospectively since 2016.

Xingzhe Li, Raquibul Hannan

Stats

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.